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Introduction {#sec005}
============

Parkinson's disease (PD) is the second most common neurodegenerative disease, and is characterized by bradykinesia, resting tremor, rigidity and postural instability. The morbidity of this chronic progressive disorder is anticipated to rise as the affected population continues live longer and increase in number.\[[@pone.0144755.ref001]\] Although the etiology of PD remains obscure, oxidative stress appears to play an important role in the progression of PD,\[[@pone.0144755.ref002]\] which results in severe degeneration and loss of dopaminergic neurons in the substantia nigra pars compacta, with subsequent development of PD.\[[@pone.0144755.ref003]\] Insulin-like growth factor-1 (IGF-1) is a 70-amino acid polypeptide chain that plays a critical role in regulating cellular function, metabolism, survival and differentiation.\[[@pone.0144755.ref004]\] The protective effect of IGF-1 against dopamine induced neurotoxicity was demonstrated in human and rodent cell cultures.\[[@pone.0144755.ref005]\] Moreover, in cell models of PD, IGF-1 was found to protect SH-EP1 cells from 1-methyl-4-phenylpyridinium (MPP^+^) induced apoptotic cell death\[[@pone.0144755.ref006]\] and augmented cellular antioxidant defense mechanisms through up-regulation of heme oxygenase-1 (HO-1) expression,\[[@pone.0144755.ref007]\] which may provide effective protection against dopaminergic neuron loss. Furthermore, behavioral recovery was observed after peripheral administration of IGF-1 in a 6-hydroxydopamine (6-OHDA) lesioned rat model of PD.\[[@pone.0144755.ref008]\] Indeed, a number of recent investigations have been conducted to evaluate serum IGF-1 levels among de novo, drug-naïve Parkinson's disease patients versus healthy controls. Nevertheless, the results from these studies are not entirely consistent.\[[@pone.0144755.ref009]--[@pone.0144755.ref013]\] Therefore, a comprehensive evaluation of serum IGF-1 levels in PD patients is necessary. To that end, the purpose of this study was to evaluate the existing literature regarding serum IGF-1 levels in de novo, drug-naïve PD patients in comparison with healthy controls, and synthesize a thorough meta-analysis which may facilitate future investigations into novel ways to diagnose, estimate prognosis and initiate early therapy in patients with PD.

Materials and Methods {#sec006}
=====================

Literature search {#sec007}
-----------------

Our study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)\[[@pone.0144755.ref014]\] ([S1 Checklist](#pone.0144755.s001){ref-type="supplementary-material"}). We searched five major electronic databases: Pubmed, ISI Web of Science, OVID, EMBASE, Cochrane library databases and reference lists up to October 2014 without language restriction. All inquiries utilized Medical Subject Headings (MeSH) with the following keywords: "insulin-like growth factor-1" or "Parkinson's disease". All articles and correlative references were evaluated for relevance to serum IGF-1 and de novo, drug-naïve PD patients. We also tried to acquire unpublished and negative results through searching the International Standard Randomized Controlled Trial Number (ISRCTN) registry and the International Clinical Trials Registry Platform (ICTRP) search portal, but no relevant studies were identified. Two authors independently performed the above literature search, with any questionable studies discussed and evaluated in detail.

Inclusion criteria {#sec008}
------------------

The eligibility of articles included in this meta-analysis were evaluated by the following inclusion criteria: (1) case-control studies comparing serum IGF-1 levels between de novo, drug-naïve idiopathic PD patients and healthy controls, or cohort studies with detailed baseline data; (2) the diagnosis of PD must be made according to the UK Parkinson's Disease Society Brain Bank\[[@pone.0144755.ref015]\]; (3) detailed methods for detecting serum IGF-1 must be available; (4) definite serum IGF-1 mean and SD values must be reported. Furthermore, two authors independently evaluated the eligibility of all identified papers based on the above inclusion criteria. Ultimately, five studies were identified and included in our meta-analysis.

Exclusion criteria {#sec009}
------------------

Review articles, commentaries, and conference proceedings without new data were excluded from this meta-analysis. Additionally, all articles pertaining to the fundamental pathophysiology of IGF-1 as related to the pathogenesis or treatment of PD were excluded. Other studies were excluded if their participants were diagnosed with secondary parkinsonism, atypical parkinsonism, familial parkinsonism or suffered from any disease that may affect serum IGF-1 levels. Two authors independently screened all articles based on the above exclusion criteria.

Quality assessment, data extraction and analysis {#sec010}
------------------------------------------------

The Newcastle-Ottawa Scale (NOS) criteria,\[[@pone.0144755.ref016]\] including the selection (0--4 points), comparability (0--2 points) and exposure (0--3 points) categories, were applied to assess the quality of all included studies, with a higher score indicating higher quality methodology. The following data were extracted from the five included studies: name of first author, year of publication, number of de novo drug-naïve PD patients and healthy controls, and the mean and standard deviation (SD) of serum IGF-1 levels. Data analysis was conducted with Cochrane Collaboration software (Review Manager 5.3) and 95% confidence intervals (CI) and mean difference (MD) were calculated. Heterogeneity, subgroup and sensitivity analyses were also carried out with Review Manager 5.3 software.

Results {#sec011}
=======

Literature search and study characteristics {#sec012}
-------------------------------------------

Initially, 35 studies were retrieved with MeSH words: "Parkinson's disease" and "insulin-like growth factor-1". After reviewing the titles and abstracts, 9 replicate studies, 8 fundamental research papers, 2 reviews and 6 other articles irrelevant to serum IGF-1 levels in PD patients were eliminated. Of the remaining 10 papers, 2 commentary papers, 1 article with no de novo drug-naïve PD patients, 1 article with plasma IGF-1 and 1 study investigating the IGF-1 gene were excluded. Ultimately, 5 studies with 166 PD patients and 323 healthy controls were included in our meta-analysis. Of these 5 studies, 2 were conducted in Germany, 2 were carried out in Italy and 1 was conducted in Japan. The selection process is further detailed in [Fig 1](#pone.0144755.g001){ref-type="fig"}. The characteristics of the 5 studies are detailed in [Table 1](#pone.0144755.t001){ref-type="table"}. The overall quality of the included studies was good as assessed by Newcastle-Ottawa Scale (NOS) criteria ([Table 2](#pone.0144755.t002){ref-type="table"}).

![Selection process of included studies in the present meta-analysis](pone.0144755.g001){#pone.0144755.g001}

10.1371/journal.pone.0144755.t001

###### Characteristics of included studies.

![](pone.0144755.t001){#pone.0144755.t001g}

  Author Name   Year   Country   N    Mean±SD of serum IGF-1   PD Definition   Variables controlled                                 
  ------------- ------ --------- ---- ------------------------ --------------- ---------------------- --------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Godau         2010   Germany   6    12                       149±30.3        98.9±23.2              \<0.001   UK Brain Criteria   BMI\>30, diabetes, cancer, thyroid disorders, dementia, chronic disease, any medication
  Godau         2011   Germany   15   139                      158.4±40.4      126.6±31               0.004     UK Brain Criteria   BMI\>30, diabetes, pitutiary of thyroid disease, chronic inflammatory disease, Cancer, use of β-blocker, corticosteroid, neuroleptic of hormone replacement medication
  Picillo       2013   Italy     55   60                       94.5±37.5       79.1±23                \<0.011   UK Brain Criteria   Secondary, familial or atypical parkinsonism, diabetes, obesity, pituitary or thyroid disease, acute or chronic inflammatory disease, cancer
  Pellecchia    2012   Italy     65   60                       91.6±34.4       79.1±23                0.019     UK Brain Criteria   atypical, secondary, familial or iatrogenic parkinsonism, dementia, major depressive disorder, disorder interfering serum IGF-1
  Numao         2014   Japan     25   52                       118.1±8.4       114.4±5.9              \>0.05    UK Brain Criteria   BMI\>30, diabetes, acromegaly, neurological disorders, dementia, psychiatric disorders, thyroid diseases

N: Number;

PD: Parkinson's disease;

CON.: Healthy Controls.

10.1371/journal.pone.0144755.t002

###### Quality assessment of included studies based on the Newcastle-Ottawa Scale.

![](pone.0144755.t002){#pone.0144755.t002g}

  Author and Year   Selection   Comparability   Exposure
  ----------------- ----------- --------------- ----------
  Godau 2010        3           2               3
  Godau 2011        3           1               3
  Picillo 2013      4           2               2
  Pellecchia 2014   4           2               2
  Numao 2014        3           2               3

The Newcastle-Ottawa Scale (NOS) criteria is composed of 3 major categories: selection (4 items), comparability (1 item) and exposure (3 items). Each item in the selection and exposure section can be awarded a maximum of one point, with a maximum of two points in the comparability section. A higher score indicates higher quality methodology.

Serum insulin-like growth factor-1 in Parkinson's disease patients {#sec013}
------------------------------------------------------------------

The random-effects model was used to calculate the pooled effect size of the five studies. All available data from the five included studies were used to compare different serum IGF-1 levels between de novo, drug naïve PD patients and healthy controls. Notably, a significant difference was found between the two groups, and the pooled mean difference in the random-effects model was 17.75, 95%CI: 6.01, 29.48 ([Fig 2](#pone.0144755.g002){ref-type="fig"}).

![Serum IGF-1 levels in PD patients compared with healthy controls.](pone.0144755.g002){#pone.0144755.g002}

Sensitivity analysis and subgroup analysis {#sec014}
------------------------------------------

Sensitivity analysis was performed to evaluate the stability and reliability of our meta-analysis by repeating analysis in various combinations of the included studies in which a single study is omitted during each reanalysis. No substantial alteration of the results were found in this sensitivity analysis, with the combined mean difference (MD) ranging from 12.70 (95% CI, 2.99, 22.41) via omission of the research by Godau 2010, to 22.72 (95% CI, 9.81, 35.64) via omission of the research by Numao 2014, indicating statistically robust results. Next, subgroup analysis was carried out to assess for heterogeneity within this meta-analysis. Due to variations among different populations' serum IGF-1 levels, this meta-analysis is highly heterogeneous (I^2^ = 81%, P\<0.0001). Therefore, we divided the total group into three subgroups according to the nation where the research was performed: Germany (N = 2), Italy (N = 2), and Japan (N = 1). These three subgroups resolved the overall heterogeneity, with study heterogeneity no longer significant in the Germany subgroup (I^2^ = 6%, P = 0.30) or the Italy subgroup (I^2^ = 0%, P = 0.71). Heterogeneity analysis is not applicable to the single study in the Japan subgroup. The various subgroups are represented by forest plots in [Fig 3](#pone.0144755.g003){ref-type="fig"}.

![Population-based subgroup analysis of serum IGF-1 levels in PD patients compared with healthy controls.](pone.0144755.g003){#pone.0144755.g003}

Discussion {#sec015}
==========

In this meta-analysis comparing different serum IGF-1 levels between de novo, drug naïve PD patients and healthy controls, we found significantly higher serum IGF-1 levels among PD patients. Although initial analysis revealed a significant degree of heterogeneity among the included studies, subgroup analysis reasonably addressed this problem by categorizing the five studies by country of origin. Unfortunately, there are no reports discussing variations in serum IGF-1 levels among German, Italian and Japanese populations. Nevertheless, population differences have been demonstrated, with significantly higher mean IGF-1 levels in healthy African-Americans compared with the Japanese population.\[[@pone.0144755.ref017]\] Indeed, these population variations may account for the obvious heterogeneity in our meta-analysis when calculating the pooled effect size. Another source of heterogeneity may be due to variations in detecting serum IGF-1. However, four different methods, including radioimmunoassay, immunoradiometric assay, and immunoassay systems, were used in the five primary studies, which makes it unlikely to contribute to the observed heterogeneity.

Among the five studies included in our investigation, three studies explored the relationship between serum IGF-1 levels and motor impairment, but with controversial results. Godau et al\[[@pone.0144755.ref011]\] found that patients with the highest serum IGF-1 levels had low UPDRS-III scores, a strong inverse correlation. However, in a 2-year follow-up study based on the Italian population, patients with the highest serum IGF-1 quartile at baseline showed significantly higher UPDRS-III scores\[[@pone.0144755.ref012]\]. Moreover, the study found that dopaminergic score rose with the IGF-1 quartile as well, which was rationalized by proposing that high IGF-1 levels at diagnosis might indicate patients with severe motor symptoms and, therefore, these patients might respond well to dopaminergic administration in the early stage of the disease.\[[@pone.0144755.ref012]\] However, no significant correlation between serum IGF-1 levels and UPDRS-III score was found in the remaining Japanese study.\[[@pone.0144755.ref013]\] The variation in outcome in each study may be attributed to inherent differences among the populations studied or might be due to inadequate sample size within each study. Therefore, to confirm whether high serum IGF-1 levels at early stages of PD is a compensatory response to neuronal degeneration or a susceptibility marker of the degenerative progress, larger cohort studies are needed.

In contrast to the controversial correlation between serum IGF-1 levels and motor dysfunction in PD patients, a recent study concluded that among the elderly population, higher serum IGF-1 levels were associated with greater cognitive function, including: working memory, selective attention and executive function.\[[@pone.0144755.ref018]\] In addition, a deficiency of IGF-1 among the elderly (\<9.4nmol/l) may influence the level and rate of decline of information process speed.\[[@pone.0144755.ref019]\] In a study by Pellecchia et al\[[@pone.0144755.ref010]\], low serum IGF-1 in de novo, drug-naïve PD patients at baseline was associated with poor performance on cognitive function after a 2 year follow-up. Therefore, we propose that a low IGF-1 level at baseline might serve as a serum biomarker for cognitive decline in PD patients through further cohort studies.

To our knowledge, this is the first meta-analysis comparing serum IGF-1 levels between PD patients and healthy controls. Our results demonstrate that serum IGF-1 levels are significantly higher in a de novo, drug-naïve PD patient cohort, which bolsters the hypothesis that elevated serum IGF-1 levels may act as a biomarker for the early diagnosis of PD; however, well-designed clinical investigations evaluating sensitivity, specificity and predictive value in the diagnosis of PD must be done to further test this hypothesis. Furthermore, additional research is necessary to verify whether high serum levels of IGF-1 at baseline could predict better outcomes during disease progression\[[@pone.0144755.ref011]\] or indicate severe motor dysfunction\[[@pone.0144755.ref012]\]. In addition, the correlation of IGF-1 levels with other clinical presentations, e.g., cognitive decline, hyposmia, psychological symptoms, or rapid eye movement sleep behavior disorder (RBD), remain to be explored. Indeed, a recent animal study found that depressed rats had significantly reduced serum IGF-1 levels.\[[@pone.0144755.ref011]\]

There are several key limitations to this meta-analysis. First, this meta-analysis was based on observational inspection, therefore, potential bias or confounding in these studies must be considered. Second, we were unable acquire unpublished data or studies with negative results, resulting in a degree of publication bias within the included studies. Thirdly, although a thorough research algorithm was used to acquire the published data, publication bias may confound the current study. Analysis of funnel plots proposed by Egger\[[@pone.0144755.ref020]\] could be a useful test to assess potential publication bias; however, according to the Cochrane Handbook, application of this method with fewer than 10 studies would be unwise.\[[@pone.0144755.ref021]\] Therefore, funnel plot analysis was not utilized in this study. In addition, since the original studies lacked gender-specific data, we were unable to conduct further analysis stratified by sex. Previous research found that estrogen can interact with IGF-1, providing neuroprotection to nigrostriatal neurons\[[@pone.0144755.ref022]\]. Moreover, estrogen can enhance transcription by interacting with enhancer response elements (EREs) and growth hormone-responsive element (GHREs) of the IGF-1 gene.\[[@pone.0144755.ref023]\] In addition, age has been reported to be inversely correlated with serum IGF-1\[[@pone.0144755.ref010]\], however, we did not acquire any age-specific data from the included studies, further confining our meta-analysis.

Conclusions {#sec016}
===========

Our meta-analysis provides evidence that de novo, drug-naïve PD patients have significantly higher serum IGF-1 levels when compared with healthy controls. Further studies should be carried out to verify these results among different populations and a well-designed cohort study should be carried out to evaluate the correlation between baseline serum IGF-1 and motor function among PD patients. In addition, the pathophysiology and biochemical mechanism of higher serum IGF-1 in PD patients could be further investigated with the hopes of unveiling potential therapeutic targets within the IGF-1 pathway.
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CI

:   Confidence interval

EREs

:   Enhancer response elements

GHREs

:   Growth hormone-responsive elements

HO-1

:   Heme oxygenase-1

IGF-1

:   Insulin-like growth factor-1

MD

:   Mean difference

MeSH

:   Medical subject headings

MPP^+^

:   1-methyl-4-phenylpyridinium

NOS

:   Newcastle Ottawa Scale

PD

:   Parkinson's disease

RBD

:   Rapid eye movement sleep behavior disorder

SD

:   Standard deviation

UPDRS

:   Unified Parkinson's disease Rating Scale

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: JL. Performed the experiments: DHL YCH. Analyzed the data: DHL YCH TJQ. Contributed reagents/materials/analysis tools: DHL YCH. Wrote the paper: DHL TJQ.
